147 related articles for article (PubMed ID: 10362362)
1. Telomerase activity in ductal carcinoma in situ and invasive breast cancer.
Umbricht CB; Sherman ME; Dome J; Carey LA; Marks J; Kim N; Sukumar S
Oncogene; 1999 Jun; 18(22):3407-14. PubMed ID: 10362362
[TBL] [Abstract][Full Text] [Related]
2. Collagenase-3 expression in breast myofibroblasts as a molecular marker of transition of ductal carcinoma in situ lesions to invasive ductal carcinomas.
Nielsen BS; Rank F; López JM; Balbin M; Vizoso F; Lund LR; Danø K; López-Otín C
Cancer Res; 2001 Oct; 61(19):7091-100. PubMed ID: 11585740
[TBL] [Abstract][Full Text] [Related]
3. Cyclooxygenase-2 expression in human breast cancers and adjacent ductal carcinoma in situ.
Half E; Tang XM; Gwyn K; Sahin A; Wathen K; Sinicrope FA
Cancer Res; 2002 Mar; 62(6):1676-81. PubMed ID: 11912139
[TBL] [Abstract][Full Text] [Related]
4. Evidence that molecular changes in cells occur before morphological alterations during the progression of breast ductal carcinoma.
Castro NP; Osório CA; Torres C; Bastos EP; Mourão-Neto M; Soares FA; Brentani HP; Carraro DM
Breast Cancer Res; 2008; 10(5):R87. PubMed ID: 18928525
[TBL] [Abstract][Full Text] [Related]
5. Telomerase activity in microdissected human breast cancer tissues: association with p53, p21 and outcome.
Mueller C; Riese U; Kosmehl H; Dahse R; Claussen U; Ernst G
Int J Oncol; 2002 Feb; 20(2):385-90. PubMed ID: 11788906
[TBL] [Abstract][Full Text] [Related]
6. [Quantitative detection of telomerase activity and its association with clinicopathological characteristics in breast cancer].
He GP; Shui QL; Huang Y; Zhang SZ; Yu H
Ai Zheng; 2004 Sep; 23(9):1041-6. PubMed ID: 15363198
[TBL] [Abstract][Full Text] [Related]
7. Carcinoma in situ of the female breast. A clinico-pathological, immunohistological, and DNA ploidy study.
Ottesen GL
APMIS Suppl; 2003; (108):1-67. PubMed ID: 12874968
[TBL] [Abstract][Full Text] [Related]
8. Ductal carcinoma in situ of the breast and heparanase-1 expression: a molecular explanation for more aggressive subtypes.
Maxhimer JB; Pesce CE; Stewart RA; Gattuso P; Prinz RA; Xu X
J Am Coll Surg; 2005 Mar; 200(3):328-35. PubMed ID: 15737842
[TBL] [Abstract][Full Text] [Related]
9. BI-RADS MRI enhancement characteristics of ductal carcinoma in situ.
Rosen EL; Smith-Foley SA; DeMartini WB; Eby PR; Peacock S; Lehman CD
Breast J; 2007; 13(6):545-50. PubMed ID: 17983393
[TBL] [Abstract][Full Text] [Related]
10. Telomerase activity in normal and neoplastic breast.
Tsao Jl; Zhao Y; Lukas J; Yang X; Shah A; Press M; Shibata D
Clin Cancer Res; 1997 Apr; 3(4):627-31. PubMed ID: 9815730
[TBL] [Abstract][Full Text] [Related]
11. Amplification of Her-2/neu gene in Her-2/neu-overexpressing and -nonexpressing breast carcinomas and their synchronous benign, premalignant, and metastatic lesions detected by FISH in archival material.
Xu R; Perle MA; Inghirami G; Chan W; Delgado Y; Feiner H
Mod Pathol; 2002 Feb; 15(2):116-24. PubMed ID: 11850540
[TBL] [Abstract][Full Text] [Related]
12. Value of sentinel lymph node biopsy in breast ductal carcinoma in situ upstaged to invasive carcinoma.
Sakr R; Antoine M; Barranger E; Dubernard G; Salem C; Daraï E; Uzan S
Breast J; 2008; 14(1):55-60. PubMed ID: 18186866
[TBL] [Abstract][Full Text] [Related]
13. The status of cyclooxygenase-2 expression in ductal carcinoma in situ lesions and invasive breast cancer correlates to cyclooxygenase-2 expression in normal breast tissue.
Leo C; Faber S; Hentschel B; Höckel M; Horn LC
Ann Diagn Pathol; 2006 Dec; 10(6):327-32. PubMed ID: 17126249
[TBL] [Abstract][Full Text] [Related]
14. Correlation between type and grade of ductal carcinoma in situ and concomitant invasive ductal carcinoma of the breast.
Rudnicka L; Stachura J
Pol J Pathol; 2000; 51(3):137-43. PubMed ID: 11247396
[TBL] [Abstract][Full Text] [Related]
15. Ductal carcinoma in situ in core biopsies containing invasive breast cancer: correlation with extensive intraductal component and lumpectomy margins.
Dzierzanowski M; Melville KA; Barnes PJ; MacIntosh RF; Caines JS; Porter GA
J Surg Oncol; 2005 May; 90(2):71-6. PubMed ID: 15844190
[TBL] [Abstract][Full Text] [Related]
16. Does ductal carcinoma in situ accompanying invasive carcinoma affect prognosis?
Chagpar AB; McMasters KM; Sahoo S; Edwards MJ
Surgery; 2009 Oct; 146(4):561-7; discussion 567-8. PubMed ID: 19789013
[TBL] [Abstract][Full Text] [Related]
17. RUNX3 inactivation by frequent promoter hypermethylation and protein mislocalization constitute an early event in breast cancer progression.
Subramaniam MM; Chan JY; Soong R; Ito K; Ito Y; Yeoh KG; Salto-Tellez M; Putti TC
Breast Cancer Res Treat; 2009 Jan; 113(1):113-21. PubMed ID: 18256927
[TBL] [Abstract][Full Text] [Related]
18. Correlation of cyclooxygenase-2 and aromatase immunohistochemical expression in invasive ductal carcinoma, ductal carcinoma in situ, and adjacent normal epithelium.
Oliveira VM; Piato S; Silva MA
Breast Cancer Res Treat; 2006 Feb; 95(3):235-41. PubMed ID: 16322898
[TBL] [Abstract][Full Text] [Related]
19. Human telomerase reverse transcriptase mRNA is highly expressed in normal breast tissues and down-regulated in ductal carcinoma in situ.
Liu J; Baykal A; Fung KM; Thompson-Lanza JA; Hoque A; Lippman SM; Sahin A
Int J Oncol; 2004 Apr; 24(4):879-84. PubMed ID: 15010825
[TBL] [Abstract][Full Text] [Related]
20. Changes in tenascin-C isoform expression in invasive and preinvasive breast disease.
Adams M; Jones JL; Walker RA; Pringle JH; Bell SC
Cancer Res; 2002 Jun; 62(11):3289-97. PubMed ID: 12036947
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
